Results 51 to 60 of about 30,003 (287)

Why is there no biosimilar of Erbitux®?

Journal of Pharmaceutical and Biomedical Analysis, 2023
Monoclonal antibody (mAb)-based therapies have been a major advance in oncology patient care, even though they represent a significant healthcare cost. Biosimilars, launched in Europe in 2004 are an economically attractive alternative to expensive originator biological drugs. They also increase the competitiveness of pharmaceutical development.
Douez, Emmanuel, D’atri, Valentina, Guillarme, Davy, Antier, Daniel, Guerriaud, Mathieu, Beck, Alain, Watier, Hervé, Foucault-Fruchard, Laura   +7 more
openaire   +4 more sources

Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries

Arthritis &Rheumatology, EarlyView.
Objective Our objective was to assess the incidence of major adverse cardiovascular events (MACEs) in patients with rheumatoid arthritis (RA) treated with JAK inhibitors (JAKi), tumor necrosis factor inhibitors (TNFi), or biologic disease‐modifying antirheumatic drugs with other modes of action (bDMARD‐OMA) in a multicountry, real‐world population ...
Romain Aymon, Denis Mongin, Romain Guemara, Zubeyir Salis, Johan Askling, Denis Choquette, Catalin Codreanu, Daniela Di Giuseppe, Irini Flouri, Doreen Huschek, Kimme L. Hyrich, Florenzo Iannone, Tore K. Kvien, Burkhard F. Leeb, Dan Nordström, Lucia Otero‐Varela, Karel Pavelka, Manuel Pombo‐Suarez, Ana Rodrigues, Ziga Rotar, Prodromos Sidiropoulos, Sella A. Provan, Anja Strangfeld, Trokovic Nina, Jakub Zavada, Lianne Kearsley‐Fleet, Delphine S. Courvoisier, Axel Finckh, Kim Lauper   +28 more
wiley   +1 more source

Science of Biosimilars [PDF]

Journal of Oncology Practice, 2017
Biosimilar therapeutic proteins in oncology offer the potential to decrease costs while providing safety and efficacy profiles consistent with their respective reference or originator products. Biosimilars have a number of important differences from generic small-molecule drugs, including manufacturing processes that are unique from their reference ...
openaire   +3 more sources

Utilization and expenditure on medicines for the management of osteoporosis in Ireland: A repeated cross‐sectional study

British Journal of Clinical Pharmacology, EarlyView.
Aim Osteoporosis is a prevalent skeletal disease characterized by low bone mass and increased fracture risk. Management of osteoporosis typically involves antiresorptive and anabolic therapies, which are reimbursed in Ireland through various drug schemes.
Amelia Smith, Lisa Kelly, Claire Gorry, Bernard Duggan, Michael Barry   +4 more
wiley   +1 more source

Native mass spectrometry combined with enzymatic dissection unravels glycoform heterogeneity of biopharmaceuticals

Nature Communications, 2018
The specific glycosylation patterns of biological drugs often impact the efficacy and safety of the therapeutic product. Here the authors describe a native mass spectrometry approach that allows the resolution of highly complex glycosylation patterns on ...
Therese Wohlschlager, Kai Scheffler, Ines C. Forstenlehner, Wolfgang Skala, Stefan Senn, Eugen Damoc, Johann Holzmann, Christian G. Huber   +7 more
doaj   +1 more source

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results [PDF]

, 2017
Background: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory diseases. The advent of biosimilar treatment options such as CT-P13 promises to improve the availability of biological therapy,
Argüelles Arias, Federico, Castro Laria, Luisa, Guerra Veloz, María Fernanda, Maldonado Pérez, Belén, Merino Bohórquez, Vicente, Perea Amarillo, Raúl, Romero Gómez, Manuel, Vilches Arenas, Ángel   +7 more
core  

PGI12 Mean Annual Cost Of Patients Hospitalized For Chronic Hepatitis C In France: The Hepc-Lone Study [PDF]

, 2014
Las relaciones laborales marítimas se singularizan por caracteres que han propiciado la necesidad de formular instrumentos que tutelen los derechos de la gente de mar. Entre las singularidades más destacadas está el centro de trabajo: el buque.
Abergel, A., Rotily, M., Gaudin, A.F., De, Léotoing L., Vainchtock, A., Akremi, R., Branchoux, S.   +6 more
core   +3 more sources

Biologics and biosimilars

Journal of Dermatological Treatment, 2015
Biological drugs are large, complex glycoprotein molecules produced in living organisms. Revolutionary treatments for many conditions, biologics used in dermatology will face patent expiration, opening opportunities for competitive versions. Biologic drugs are so complex such that it is impossible to reproduce them exactly.
Caleb R King, Palak K Patel, Steven R. Feldman   +2 more
openaire   +3 more sources

Biosimilars and Regulatory Authorities [PDF]

Nephron Clinical Practice, 2010
The patent expirations for many biotechnological medicines have prompted the development of copies of biological medicinal products. Unlike generics, biosimilars are similar but not identical to their reference product, because their chemical characteristics are directly related to the manufacturing process which cannot be precisely duplicated.
P. Minghetti, P. Rocco, L. Del Vecchio, F. Locatelli   +3 more
openaire   +3 more sources

A single‐centre analysis of a biosimilar switching programme for adalimumab in inflammatory bowel disease

British Journal of Clinical Pharmacology, EarlyView.
Aims Amgevita is a licensed biosimilar to adalimumab, having demonstrated high pharmacokinetic and clinical similarity to Humira. Switching to a lower‐cost medicine may elicit a nocebo effect, whereby expectations of poorer efficacy impact outcomes despite pharmacological similarity. This prospective cohort study examined clinical and economic outcomes
Louise Rabbitt, Áine Keogh, Linda Duane, John Ferguson, Anna Hobbins, Brian E. McGuire, Patrick Gillespie, Laurence J. Egan   +7 more
wiley   +1 more source